Skip to main content

Table 3 Summary of previous studies using aflibercept for neovascular age-related macular degeneration (nvAMD) with a treat-and-extend (TAE) regime

From: Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration

Prospective studies

Study

n

Mean age

Mean baseline VA (ETDRS letters)

Visual change (ETDRS letters)

Number of injections

Treatment näive

Ohji et al. (ALTAIR) [19]

124a

NA

NA

+ 9.0 (1y)

7.2

Yes

123b

NA

NA

+ 8.4 (1y)

6.9

Haga et al. [6]

21

75.5

56.9

+ 15.9 (1y)

7.5

NR

DeCroos et al. (ATLAS) [5]

35

81.3

58.9

+ 7.2 (1y)

8.0

Yes

Hatz et al. [20]

33

81.0

66.8

− 0.6 (1y)

NR

No

Jørstad et al. [21]

50

NR

72.5g

+ 0.5(1y)g

9.2

No

Retrospective studies

Study

n

Mean age

Mean baseline VA (ETDRS letters)

Mean visual gain (ETDRS letters)

Number of injections

Treatment näive

Barthelmes et al. [7]

136

77.2

61.4

+ 6.0 (2y)

13.6

Yes

Matsumoto et al. [8]

18c

75.7

53.5g

+ 9.5 (1y)g

7.7

Yes

44d

71.5

72.0g

+ 7.0 (1y)g

8.3

Yes

58e

72.4

71.5g

+ 8.0 (1y)g

7.7

Yes

5f

77.2

56.5g

+ 14.5 (1y)g

7.3

Yes

Matsumoto et al. [9]

60

75.1

69.5g

+ 9.0 (1y)g

13.8 (2y)

Yes

Ohnaka et al. [10]

36

72.3

61.0g

+ 4 (1y)g

4.5

Yes

Yamamoto et al. [11]

67

NA

70.5g

+ 7.5 (1y)g

8.3

NA

Ito et al. [12]

61

NA

NA

+ 6.5 (2y)g

13.6

Yes

Castro-Navarro et al. [13]

30

78.8

54.5g

+ 11.5 (1y)g

7.7

Yes

Unsal et al. [14]

38

74.5

39.1

+ 15.9 (1y)

4.9

Yes

Ishibashi et al. [15]

39

75.5

63.9

+ 6.5 (1y)

7.9

Mixed

Wakuta et al. [16]

16

78.3

65

0 (1y)

7.8 (1y)

Mixed

Current Study

213

80.4

40.0

+ 10.1 (1y)

7.4

Yes

  1. ETDRS Early Treatment Diabetic Retinopathy Study; VA visual acuity; NR not reported; NA not available; 1y one year; 2y two year
  2. a2-week adjustment of treat-and-extend regime
  3. b4-week adjustment of treat-and-extend regime
  4. cClassic (type I) choroidal neovascularization
  5. dOccult (type I) choroidal neovascularization
  6. ePCV polypoidal choroidal vasculopathy
  7. fRAP retinal angiomatous proliferation
  8. gValues reported in logarithm of the minimal angle (logMAR) and converted to approximate ETDRS letters for table